Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial.
Karama AslehHeather Ann BrauerAmy SullivanSusanna LauttiaHenrik LindmanTorsten O NielsenHeikki JoensuuE Aubrey ThompsonSaranya ChumsriPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Genes and metagenes related to antitumor immunity, immune response, and capecitabine activation could identify TNBC patients who are more likely to benefit from adjuvant capecitabine. Given the reduced power to observe significant findings when correcting for multiplicity, our findings provide the basis for future hypothesis-testing validation studies on larger clinical trials.
Keyphrases
- early stage
- clinical trial
- phase iii
- immune response
- end stage renal disease
- phase ii study
- locally advanced
- metastatic breast cancer
- metastatic colorectal cancer
- chronic kidney disease
- ejection fraction
- open label
- newly diagnosed
- phase ii
- prognostic factors
- double blind
- peritoneal dialysis
- randomized controlled trial
- sentinel lymph node
- genome wide
- radiation therapy
- study protocol
- gene expression
- neoadjuvant chemotherapy
- transcription factor
- inflammatory response
- case control